BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05, Zacks reports. The business had revenue of $180.29 million for the quarter, compared to the consensus estimate of $165.67 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The firm’s revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.06 EPS.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• ORLADEYO revenue was $174.8 million, up 20% year over year excluding Europe, but included an upper-teens-million-dollar, one-time contribution from CareMed’s inventory build. BioCryst kept its full-year ORLADEYO guidance at $625 million–$645 million, saying future revenue should more closely reflect patient demand.
• BioCryst reported non-GAAP operating profit of $86 million, up 70% year over year, and non-GAAP net income of $71 million, more than doubling. It raised total 2026 revenue guidance to $715 million–$730 million, tightened operating expense guidance to $415 million–$425 million, and expects restructuring actions to generate $30 million–$35 million in annualized savings.
• Management described ORLADEYO prescriptions and net patient additions as strong, with early pediatric demand ahead of expectations and potential to exceed the previously estimated 500-patient opportunity. The company also launched pediatric pellets and plans to offer a newly approved 150 mg pellet formulation for patients 12 and older.
• The navenibart pivotal trial is fully enrolled, with 12-month top-line data expected in the third quarter of 2027; BioCryst is also preparing its BLA and launch plans. The company expects early BCX17725 data in Netherton syndrome by year-end and is evaluating early-stage external opportunities, but said further investment and development decisions will depend on the data and scientific assessment.

BioCryst Pharmaceuticals Trading Up 0.8%

Shares of BioCryst Pharmaceuticals stock traded up $0.07 during trading on Wednesday, reaching $8.63. The stock had a trading volume of 1,931,364 shares, compared to its average volume of 4,885,920. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -5.76 and a beta of 0.55. The stock has a fifty day moving average price of $8.58 and a two-hundred day moving average price of $8.74. BioCryst Pharmaceuticals has a 52 week low of $6.23 and a 52 week high of $11.22.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 24th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Royal Bank Of Canada lowered BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $13.00 to $11.00 in a research report on Thursday, September 10th. Wedbush lowered their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. lifted their price target on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 30th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $20.75.

Trending Headlines about BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: BioCryst earned $0.14 per share, topping the $0.09 consensus estimate and improving on $0.06 a year earlier. Revenue was $180.29 million, above the $165.67 million estimate and up 13.1% year over year. The company also raised its guidance. BioCryst Q3 earnings and raised guidance BioCryst third-quarter financial results
• Negative Sentiment: Despite the quarterly earnings beat, BioCryst continues to report a negative net margin and negative return on equity, indicating that profitability remains a concern. BioCryst earnings report

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.